Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CES 2022: Abbott CEO Robert Ford Announces New Biowearables Line For Consumers, Paving The Way From Measuring Glucose To Ketone, Lactate, Alcohol

Executive Summary

Abbott announced today at CES 2022 it is developing a new line of consumer wearables, starting with a device to track ketones continuously, which is expected to launch in Europe this year. 

You may also be interested in...



Minute Insight: Abbott Is Planning To Combine Glucose And Ketone Measurement Into One Wearable

The company announced that it is developing a new biowearable device that will continuously monitor both glucose and ketone levels with one sensor.

Minute Insight: Withings Continues Push Into Wearables With Two Acquisitions

The consumer device company recently bought 8Fit, a German fitness app developer, and Impeto Medical, the developer of the Sudoscan technology for detecting and tracking small fiber neuropathy.

Digital Health Roundup: Digital Therapeutics, Restoring Function, Deals, Investing And Lobbying

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel